

REMARKS:

In response to the Restriction Requirement dated July 9, 2007, the response term having been extended by two months, the applicants hereby elect Group III, with traverse. In response to the further election requirement made by the Examiner, with respect to the human homologues of Table 1 of the specification, the applicants select the first named human homologue of CG 7826 of Table 1, namely Dyrk1a-Isoform 1.

As indicated, these elections are with traverse. The present application is a national phase entry from a PCT international application, and no lack of unity objection was raised during the international phase. The comments presented by the Examiner to support the restriction requirements seem to imply that the Examiner was unaware that this restriction requirement has to comply with the PCT Rules, and accordingly, it is believed that the Restriction Requirement should be withdrawn, and the application examined on the merits.

The use claims in this application, which are the European version of method of treatment claims, have been rewritten into U.S. style method of treatment claims.

Early and favorable action on the merits is awaited.

Respectfully submitted,

\Robert B. Murray\

By

Robert B. Murray
Attorney for Applicant
Registration No. 22,980
ROTHWELL, FIGG, ERNST & MANBECK
1425 K. Street, Suite 800
Washington, D.C. 20005
Telephone: (202) 783-6040

RBM/cb